Annovis Bio, Inc. (ANVS) Stock Forecast
ANVS analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.75 / 5 from 4 analysts
- Price target
- $10.50 average of analyst targets
- Upside to target
- +960.6% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.30
- 52-week range
- $0.99 – $5.10
ANVS analyst ratings
4 analystsNumber of analysts at each rating.
ANVS price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ANVS earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.33 | −$0.36 | −$0.30 | −$0.37 | +10.8% | 2 |
| Current fiscal year (2026) | −$1.45 | −$1.58 | −$1.32 | −$1.40 | −3.6% | 2 |
| Next fiscal year (2027) | −$0.86 | −$1.18 | −$0.54 | −$1.45 | +40.7% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ANVS revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 3 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 3 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 3 |
ANVS EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ANVS EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.44 | −$0.44 | −$0.37 | −$0.33 | −$0.33 | −25.0% | 1 up · 0 down |
| Current fiscal year (2026) | −$1.80 | −$1.80 | −$1.69 | −$1.45 | −$1.45 | −19.4% | 1 up · 0 down |
| Next fiscal year (2027) | −$1.16 | −$1.16 | −$0.89 | −$0.86 | −$0.86 | −25.9% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ANVS earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ANVS beat in 6 of 12.
What analysts expect from ANVS
4 analysts cover Annovis Bio; their consensus rating is strong buy (4.75 on a 1–5 scale, where 5 is a strong buy). The average price target is $10.50, 960.6% above the latest close of $0.99. Analysts expect earnings of −$1.45 per share for 2026, −3.6% from a year earlier. For 2027 the average estimate is −$0.86 per share. Annovis Bio beat the EPS estimate in 6 of the last 12 quarters.
Related: ANVS income statement, ANVS key metrics, ANVS chart. See the ANVS stock overview for the latest quote and news.
ANVS forecast FAQ
What is Annovis Bio's price target?
The average analyst price target for Annovis Bio is $10.50, 960.6% above the latest close of $0.99.
Is Annovis Bio a buy, hold or sell?
Of 4 analysts covering Annovis Bio, 3 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Annovis Bio's EPS forecast?
Analysts forecast −$1.45 per share for 2026 (range −$1.58 to −$1.32); for 2027 the estimate is −$0.86.
When does Annovis Bio report earnings?
Annovis Bio is expected to report results for the quarter ending September 30, 2026 on November 11, 2026; the EPS estimate is $-0.30.
Does Annovis Bio usually beat earnings estimates?
Annovis Bio reported EPS at or above the analyst estimate in 6 of the last 12 quarters.